c. difficile infection News
-
Artugen is currently enrolling in C. difficile infection study.
Artugen is currently enrolling subjects in “A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a C. difficileinfection” We are looking for volunteers to participate in a new study to help lower the recurrence rate of C. difficile infections. If you are someone who was diagnosed, treated, and recovered from the infection and are ...
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in ...
-
C. diff Infections are a Real Concern in Chicago & across Illinois
The environmental and infection control experts at EC2 provide prevention services, inspections and solutions for healthcare facilities battling C. diff threats. Just last week it was reported that an outbreak of C. difficile (C. diff) at a Canadian hospital has already infected 63 patients. The outbreak has caused at least one confirmed death and possibly six others. This latest ...
-
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. Located at the Strathclyde Business Park in Bellshill, the 20,000-square-foot facility is designed to meet regulatory biologics requirements and product analysis while providing the company end-to-end control of its supply chain, ...
-
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent ...
-
Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection
FDA clearance of investigational new drug (IND) application Initiation of multisite Phase 2 study in spring 2022 Phase 1 pharmacokinetic study completed Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. ...
-
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Food and Drug Administration (FDA) has ...
-
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Research from the Phase 3 PUNCH CD3 trial on the effects of RBX2660 on deadly ...
-
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to ...
-
Artugen Therapeutics Announces First Patient Dosed with ART24, Artugen`s first clinical product candidate for prevention of recurrence of Clostridium difficile infection
ART24 granted Fast Track Designation First Patient Dosed Concord, Mass., and Dublin, Ireland March 12, 2020 — Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention ...
-
Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection
SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it has paused enrollment in ...
-
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 20%. This ...
-
Clostridium difficile Infections Rise Dramatically in Children
Researchers at the Mayo Clinic recently discovered that the incidence of Clostridium difficile (also known as C. diff, CDI and C. difficile) infections in children has risen dramatically in recent years. They found that infections rates between 2004 and 2009 were 12 times higher than the rates recorded between 1991 and 1997. C. diff is a bacterium that is found in the environment and ...
-
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can ...
-
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
-
AHE Announces Speaker Lineup for EXCHANGE 2013 Conference
Chicago, June 26, 2013 - The Association for the Healthcare Environment (AHE) of the American Hospital Association today announced its lineup of keynote speakers and general sessions at EXCHANGE 2013 being held September 15-18 in Indianapolis, Ind. The lineup of speakers includes: Simon T. Bailey, founder, Brilliance Institute, a world-renowned speaker, thought leader, and best-selling author ...
-
Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020
Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection These data presentations strengthen the company’s leadership and scientific and clinical understanding of the two investigational ...
-
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of ...
-
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
Researchers describe rapid, low-cost drug development approach Paper also reports preclinical and early clinical data for LMN-101 A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience report in Nature ...
-
Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases. The first is a $5 million grant from the Bill & Melinda Gates Foundation for a second Phase 2 study of an improved anti-campylobacter therapeutic, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you